Skip to main content

Advertisement

Table 1 Characterization of patients with Alzheimer’s disease and healthy normal control subjects

From: Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42

  AD Healthy normal control subjects
Total sample number 24 29
Sex
 Female 13 (54.2%) 16 (55.2%)
 Male 11 (45.8%) 13 (44.8%)
Age, years (SD) 67.6 (±7.4) 62.4 (±5.7)
Education, years (SD) 13.1 (±3.9) 13.2 (±3.5)
CDR-SOB, mean 6.35 0.03
MMSE score, mean 17.7 29.03
ApoE ε4, % 47.8 21.7
 Note test 1 0
Number of plasma samples 24 29
CSF markers 23 28
 Aβ42, pg/ml, mean (SD) 258.6 (±70.8) 464.8 (±114.4)
 p-Tau, pg/ml, mean (SD) 58.6 (±18.6) 28.0 (±14.3)
 t-Tau, pg/ml, mean (SD) 132.1 (±61.8) 62.1 (±20.3)
PiB-PET number 23 28
 Mean SUVR 1.57 1.14
FDG-PET number 18 28
 Mean SUVR 0.9 1.06
  1. Abbreviations: Aβ 42 Amyloid-β 1–42 peptide, AD Alzheimer’s disease, ApoE Apolipoprotein E, CDR-SOB Clinical Dementia Rating Sum of Boxes, CSF Cerebrospinal fluid, FDG 18F-fluorodeoxyglucose, MMSE Mini Mental State Examination, PET Positron emission tomography, PiB 11C-Pittsburgh compound B, p-Tau Phosphorylated tau protein, SUVR Standardized uptake value ratio, t-Tau Total tau protein